News
Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...
Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...
Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...
After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...
Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...
Biogen Inc. has announced a $2 billion investment to expand its manufacturing capabilities at Research Triangle Park (RTP), ...
Since starting operations in North Carolina 30 years ago, Biogen has spent approximately $10 billion to bolster its ...
Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat ...
In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...
Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results